In this edition we feature:
S1826 trial: N-AVD vs. BV-AVD in advanced-stage cHL
S1826 trial: elderly subgroup analysis
GHSG HD21 trial: PET-adapted BrECADD for elderly advanced-stage cHL
MTV2 for response assessment in advanced-stage HL
LymphoVista HL: a validated MRD assay in HL
NLPHL in Nordic nations
Pembrolizumab maintenance instead of transplant with complete response after P-GVD in relapsed/refractory Serum TARC dynamics, MTV & clinical response in first-line N-AVD treatment of cHL
GHSG-NLG BVB trial: first-line BV-CAP in advanced-stage HL ≥60 years
A frailty score to predict survival in elderly cHL
Serum TARC + FDG-PET to improve early response assessment in cHL
Risks of toxicities after radiotherapy for HL
Please login below to download this issue (PDF)